Literature DB >> 16707030

Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users.

J Amin1, M G Law, J Micallef, M Jauncey, I Van Beek, J M Kaldor, G J Dore.   

Abstract

Estimates of hepatitis C virus (HCV) clearance following acute infection range from 14 to 46%. This wide range is likely to be due to the characteristics of the populations studied and analysis methods. This paper examines how differing definitions of clearance parameters affect estimates of viral clearance in a cohort of 85 injecting drug users with newly acquired HCV infection. Kaplan-Meier estimates of time to HCV clearance were determined using varying definitions of eligible cohort, viral clearance, date of infection and date of clearance. Based on which combinations of definitions were used, the number of subjects eligible for analysis ranged from 27 to 75, clearance rate ranged from 14 to 68% and time to achieving 25% clearance ranged from approximately 5 months to 14 months. Standardized definitions and methodologies are required to enable valid comparisons of rates of clearance across newly acquired HCV infection natural history studies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16707030      PMCID: PMC2870537          DOI: 10.1017/S0950268806006388

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  18 in total

1.  The practical significance of potential biases in estimates of the AIDS incubation period distribution in the UK register of HIV seroconverters.

Authors:  K Porter; A M Johnson; A N Phillips; J H Darbyshire
Journal:  AIDS       Date:  1999-10-01       Impact factor: 4.177

2.  Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies.

Authors:  Alberto Larghi; Massimo Zuin; Andrea Crosignani; Maria Lisa Ribero; Cristina Pipia; Pier Maria Battezzati; Giorgio Binelli; Francesco Donato; Alessandro Remo Zanetti; Mauro Podda; Alessandro Tagger
Journal:  Hepatology       Date:  2002-10       Impact factor: 17.425

Review 3.  Natural history of chronic hepatitis C.

Authors:  Leonard B Seeff
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

4.  Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients.

Authors:  Giovanna Fattovich; Maurizio Pantalena; Irene Zagni; Giuseppe Realdi; Solko W Schalm; Erik Christensen
Journal:  Am J Gastroenterol       Date:  2002-11       Impact factor: 10.864

5.  Analysis of the viability of freezer stored serum samples for hepatitis C virus RNA analysis by the SUPERQUANT method: results of a 16 year retrospective study.

Authors:  P Schmid; M Tong; A Conrad; J McHutchison; L M Blatt
Journal:  J Virol Methods       Date:  1999-10       Impact factor: 2.014

6.  Incident hepatitis C virus infection in a community-based population in Japan.

Authors:  A Okayama; S O Stuver; E Tabor; N Tachibana; M Kohara; N E Mueller; H Tsubouchi
Journal:  J Viral Hepat       Date:  2002-01       Impact factor: 3.728

7.  Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001.

Authors:  Matthew G Law; Gregory J Dore; Nicky Bath; Sandra Thompson; Nick Crofts; Kate Dolan; Wendy Giles; Paul Gow; John Kaldor; Stuart Loveday; Elizabeth Powell; Jenean Spencer; Alex Wodak
Journal:  Int J Epidemiol       Date:  2003-10       Impact factor: 7.196

8.  Clearance of hepatitis C virus after newly acquired infection in injection drug users.

Authors:  Marianne Jauncey; Joanne M Micallef; Stuart Gilmour; Janaki Amin; Peter A White; William Rawlinson; John M Kaldor; Ingrid van Beek; Gregory J Dore
Journal:  J Infect Dis       Date:  2004-08-18       Impact factor: 5.226

9.  Viral clearance occurs very early during the natural resolution of hepatitis C virus infection in persons with haemophilia.

Authors:  M E Eyster; J Sanders; J J Goedert
Journal:  Haemophilia       Date:  2004-01       Impact factor: 4.287

10.  Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load.

Authors:  Harald Hofer; Thomas Watkins-Riedel; Oskar Janata; Edward Penner; Heidemarie Holzmann; Petra Steindl-Munda; Alfred Gangl; Peter Ferenci
Journal:  Hepatology       Date:  2003-01       Impact factor: 17.425

View more
  13 in total

Review 1.  Hepatitis infection in the treatment of opioid dependence and abuse.

Authors:  Thomas F Kresina; Diana Sylvestre; Leonard Seeff; Alain H Litwin; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Subst Abuse       Date:  2008-04-28

2.  Prospective follow-up of patients with acute hepatitis C virus infection in Brazil.

Authors:  Lia L Lewis-Ximenez; Georg M Lauer; Julian Schulze Zur Wiesch; Paulo Sergio Fonseca de Sousa; Cleber F Ginuino; Gláucia Paranhos-Baccalá; Hanno Ulmer; Karl P Pfeiffer; Georg Goebel; João Luiz Pereira; Jaqueline Mendes de Oliveira; Clara Fumiko Tachibana Yoshida; Elisabeth Lampe; Carlos Eduardo Velloso; Marcelo Alves Pinto; Henrique Sergio Coelho; Adilson José Almeida; Carlos Augusto Fernandes; Arthur Y Kim; Alexander M Strasak
Journal:  Clin Infect Dis       Date:  2010-05-01       Impact factor: 9.079

3.  Antibody dynamics and spontaneous viral clearance in patients with acute hepatitis C infection in Rio de Janeiro, Brazil.

Authors:  Alexander M Strasak; Arthur Y Kim; Georg M Lauer; Paulo S de Sousa; Cleber F Ginuino; Carlos A Fernandes; Carlos E Velloso; Adilson J de Almeida; Jaqueline M de Oliveira; Clara F Yoshida; Julian Schulze zur Wiesch; Gláucia Paranhos-Baccalá; Stefan Lang; Larry J Brant; Hanno Ulmer; Susanne Strohmaier; Lalit Kaltenbach; Elisabeth Lampe; Lia L Lewis-Ximenez
Journal:  BMC Infect Dis       Date:  2011-01-12       Impact factor: 3.090

4.  Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection.

Authors:  Jason Grebely; Kathy Petoumenos; Margaret Hellard; Gail V Matthews; Vijayaprakash Suppiah; Tanya Applegate; Barbara Yeung; Phillipa Marks; William Rawlinson; Andrew R Lloyd; David Booth; John M Kaldor; Jacob George; Gregory J Dore
Journal:  Hepatology       Date:  2010-10       Impact factor: 17.425

5.  Natural history of HCV infection.

Authors:  Shiv K Sarin; Manoj Kumar
Journal:  Hepatol Int       Date:  2012-03-09       Impact factor: 6.047

6.  Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection.

Authors:  Kimberly Page; Judith A Hahn; Jennifer Evans; Stephen Shiboski; Paula Lum; Eric Delwart; Leslie Tobler; William Andrews; Lia Avanesyan; Stewart Cooper; Michael P Busch
Journal:  J Infect Dis       Date:  2009-10-15       Impact factor: 5.226

7.  Evaluation of operational chronic infection endpoints for HCV vaccine trials.

Authors:  Minhee Kang; Uwe Nicolay
Journal:  Contemp Clin Trials       Date:  2008-04-09       Impact factor: 2.226

8.  Prevalence of hepatitis C virus in young people who inject drugs in four Colombian cities: A cross-sectional study using Respondent Driven Sampling.

Authors:  David Toro-Tobón; Dedsy Berbesi-Fernandez; Pedro Mateu-Gelabert; Ángela M Segura-Cardona; Liliana P Montoya-Vélez
Journal:  Int J Drug Policy       Date:  2018-08-11

9.  Role of IL28B gene polymorphism and cell-mediated immunity in spontaneous resolution of acute hepatitis C.

Authors:  Enea Spada; Pietro Amoroso; Gloria Taliani; Ornella Zuccaro; Piergiorgio Chiriacò; Patrizia Maio; Giuseppe Maio; Maria Luisa Esposito; Corrado Mariano; Roberto Rinaldi; Pietro Bellissima; Maria Elena Tosti; Paola Del Porto; Ruggiero Francavilla; Vincenzo Mellace; Anna Rosa Garbuglia; Antonella Folgori; Alfonso Mele
Journal:  Clin Infect Dis       Date:  2013-06-19       Impact factor: 9.079

10.  Many hepatitis C reinfections that spontaneously clear may be undetected: Markov-chain Monte Carlo analysis of observational study data.

Authors:  Rachel Sacks-Davis; Emma McBryde; Jason Grebely; Margaret Hellard; Peter Vickerman
Journal:  J R Soc Interface       Date:  2015-03-06       Impact factor: 4.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.